Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom

Pediatrics

Volumn 121, Issue 5, 2008, Pages 1002-1009

  Rani, Fariz ^a,b   Murray, Macey L ^a,b,c   Byrne, Patrick J ^d,e   Wong, Ian C K ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Task force in Europe for Drug Development for the Young (TEDDY) Network of Excellence   (United Kingdom)

^d BETHLEM ROYAL HOSPITAL   (United Kingdom)

^e SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotics; Drug utilization; Pediatric; Pharmacoepidemiology

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENPERIDOL; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PROMAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD HEALTH CARE; CONFIDENCE INTERVAL; DRUG UTILIZATION; GENERAL PRACTICE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PEDIATRICS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UNITED KINGDOM; PRESCHOOL CHILD; STATISTICS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FAMILY PRACTICE; GREAT BRITAIN; HUMANS; INFANT; THIORIDAZINE;

EID: 44449097249     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-2008     Document Type: Article

References (31)

1. Bramble D. Annotation: the use of psychotropic medications in children: a British view. J Child Psychol Psychiatry. 2003;44(2): 169-179
2. Frangou S, Byrne P. How to manage the first episode of schizophrenia. BMJ. 2000;321(7260):522-523
3. Anderson L, Campbell M, Grega D, Perry R, Small A, Green W. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry. 1984; 141(10):1195-1202
4. Naruse H, Nagahata M, Nakane Y, Shirahashi K, Takesada M, Yamazaki K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr. 1982;48(4):173-184
5. Shapiro E, Shapiro A, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1989;46(8):722-730
6. Malone R, Sheikh R, Zito J. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv. 1999; 50(2):171-174
7. Cheng-Shannon J, McGough J, Pataki C, McCracken J. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14(3):372-394
8. DuBois D. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr. 2005;17(2):227-233
9. Haddad P, Wieck A. Antipsychotic-induced hyperprolactinaemia. Drugs. 2004;64(20):2291-2314
10. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62(11):1649-1671
11. Armenteros JL, Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2006;15(3):141-148
12. Schirm E, Tobi H, Zito JM, de Jong-van den Berg LTW. Psychotropic medication in children: a study from the Netherlands. Pediatrics. 2001;108(2). Available at: www.pediatrics.org/cgi/content/full/108/2/e25
13. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158(8):753-759
14. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685
15. Sutcliffe AG, Wong ICK. Rational prescribing for children. BMJ. 2006;332(7556):1464-1465
16. Wong ICK, Murray ML, Camilleri-Novak D, Stephens P. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89(12):1131-1132
17. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends. 1997;87(87):36-40
18. Wood L, Martinez C. The General Practice Research Database: role in pharmacovigilance. Drug Saf. 2004;27(12):871-881
19. Medicines and Healthcare Products Regulatory Agency. The General Practice Research Database. Available at: www.gprd. com. Accessed June 27, 2006
20. Joint Formulary Committee. British National Formulary. 54th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2007
21. Rey JM, Sawyer MG. Are psychostimulant drugs being used appropriately to treat child and adolescent disorders? Br J Psychiatry. 2003;182(4):284-286
22. Committee on Safety of Medicines. Thioridazine: restricted indications and new warnings on cardiotoxicity. Available at: www.info.doh.gov.uk/doh/ embroadcast.nsf/f011981a95f31f4 180256c07003d34a0/ fc5d1f63a16da86b80256dad00480816? OpenDocument. Accessed June 13, 2006
23. Coghill D. Current issues in child and adolescent psychophar- macology, part 2: anxiety and obsessive-compulsive disorders, autism, Tourette's and schizophrenia. Adv Psychiatr Treat. 2003; 9:289-299
24. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006;368(9531): 210-215
25. Murray ML, de Vries CS, Wong ICK. A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child. 2004;89(12): 1098-1102
26. Committee on Safety of Medicines. Selective serotonin re-uptake inhibitors: use in children and adolescents with major depressive disorder. Available at: www.info.doh.gov.uk/doh/embroadcast.nsf/0/ 183a970c6d74afad80256df800330c99/$FILE/CEM2003-20.doc. Accessed June 22, 2006
27. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363(9418):1341- 1345
28. Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2001;3(12):927-942
29. Campbell EG, Russell LG, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med. 2007;356(17):1742-1750
30. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care: clinical guideline 1, December 2002. Available at: guidance.nice.org.uk/CG1/niceguidance/pdf/ English. Accessed April 17, 2007
31. Montoliu L, Crawford T. Prescribing practices of general practitioners for children with mental health problems. Child Adolesc Mental Health. 2002;7(3):128-130